Induced pluripotent stem cells, or iPS cells (iPSCs), are ordinary body cells that have been reprogrammed back into a flexible, embryo-like state. In this state, they can become virtually any cell type in the human body: heart muscle, brain neurons, liver cells, retinal tissue, and more. Shinya Yamanaka first created them from mouse skin cells in 2006, a discovery that earned him the Nobel Prize in Physiology or Medicine in 2012, shared with Sir John B. Gurdon.
How Ordinary Cells Become Pluripotent
Every cell in your body carries the same DNA, but most cells have locked themselves into a specific identity. A skin cell “knows” it’s a skin cell because chemical tags on its DNA keep certain genes switched off and others switched on. Reprogramming reverses that lock.
To make iPS cells, researchers introduce four specific proteins into a mature cell, typically from skin or blood. These proteins, known as the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc), are transcription factors that normally operate in embryonic cells. When forced into an adult cell, they begin stripping away the chemical tags that define that cell’s identity. DNA packaging loosens, silenced genes reactivate, and the cell gradually reverts to a state where it can become anything again.
The process unfolds in phases. First, the cells must survive and begin dividing. Then comes a stochastic, somewhat unpredictable phase where some cells in a batch reprogram successfully while others don’t. The key turning point is when the cell’s own pluripotency genes (particularly one called Nanog) switch on independently, without help from the introduced factors. Once that internal loop is running on its own, the cell has irreversibly committed to its new pluripotent identity. The whole process takes roughly two to three weeks, though efficiency remains a challenge. Early methods converted fewer than 0.001% of treated cells. Newer techniques using small molecules and optimized delivery methods have pushed that number much higher, with some labs reporting nearly 100% of resulting colonies showing full reprogramming markers.
How iPS Cells Compare to Embryonic Stem Cells
Embryonic stem cells (ESCs) are the original gold standard for pluripotency. They’re harvested from early-stage embryos and can become any cell type. iPS cells were designed to match that ability without requiring embryos, sidestepping the ethical concerns that have limited ESC research funding and progress for decades.
On the surface, iPS cells and embryonic stem cells look remarkably similar. They express the same core pluripotency genes, they can differentiate into the same broad range of tissues, and they form similar structures in lab dishes. But they’re not identical. Genetic comparisons have revealed that iPS cells sometimes carry abnormal imprinting patterns, particularly at a gene cluster on chromosome 12 called Dlk1-Dio3. In these cells, genes inherited from the mother are silenced while genes from the father are overexpressed. Mouse iPS cells with this imprinting error cannot generate an entire organism in the most stringent test of pluripotency, something properly imprinted embryonic stem cells can do.
The practical significance of these differences is still being sorted out. For many research and therapeutic applications, the differences may not matter. But they do mean iPS cells can’t simply be assumed to behave identically to embryonic stem cells in every context.
The Biggest Advantage: Immune Compatibility
The most transformative feature of iPS cells is that they can be made from a patient’s own body. This matters enormously for transplant medicine. Embryonic stem cells come from a donor embryo, meaning any tissues grown from them would be genetically foreign to the recipient. The patient’s immune system would attack those cells just as it would attack a transplanted organ, requiring lifelong immunosuppressive drugs.
iPS cells created from your own skin or blood are a genetic match. In primate studies directly comparing the two approaches, neurons grown from an animal’s own iPS cells triggered only a minimal immune response when transplanted into the brain. Neurons from a donor animal’s iPS cells, by contrast, provoked a clear immune reaction, with immune cells infiltrating the graft site. More donor-derived neurons died as a result.
The tradeoff is cost and time. Creating a personalized iPS cell line for each patient is expensive and labor-intensive. An alternative strategy involves building banks of iPS cell lines from donors with common immune profiles (HLA types) that can be matched to large segments of the population, similar to blood type matching. This approach sacrifices perfect compatibility for practical scalability.
Disease Modeling and Drug Discovery
Before iPS cells ever reach a patient’s body, they’re already changing medicine in the lab. Researchers can take cells from a person with a genetic disease, reprogram them into iPS cells, and then grow them into the specific tissue affected by the disease. The result is a living, human model of that disease in a dish.
This has been done successfully for a wide range of conditions. Researchers have created iPS-derived neurons from patients with Alzheimer’s disease, Parkinson’s disease, ALS, Huntington’s disease, and schizophrenia. They’ve grown heart cells from patients with dangerous heart rhythm disorders like long QT syndrome and Brugada syndrome. They’ve modeled spinal muscular atrophy, Rett syndrome, and liver diseases. In each case, the lab-grown cells displayed the actual disease characteristics seen in patients, providing a window into what goes wrong at the cellular level.
These models are particularly valuable for testing drugs. In one study, researchers grew neurons from schizophrenia patients and tested several antipsychotic medications on them. One drug, loxapine, was found to increase the growth of neural connections between cells, revealing a possible mechanism that couldn’t have been observed in animal models. In ALS research, a compound called kenpaullone was identified as a candidate for improving motor neuron survival after being tested on iPS-derived neurons carrying the same mutation found in patients. Heart cells grown from iPS cells are now being used to screen drugs for cardiac toxicity before they ever enter human trials, potentially catching dangerous side effects much earlier in the development process.
Clinical Trials and Current Progress
As of December 2024, 115 clinical trials in 19 countries are testing therapies derived from human pluripotent stem cells (both iPS cells and embryonic stem cells) across 34 different medical conditions. The majority target eye diseases, central nervous system disorders, and cancer. Most of these trials are still in early phases, focused on establishing safety rather than proving effectiveness.
The very first clinical use of iPS cells was for age-related macular degeneration, a leading cause of blindness. In 2013, Masayo Takahashi and the RIKEN Institute in Japan transplanted retinal pigment cells grown from a patient’s own iPS cells into the eye. A separate trial at Moorfields Eye Hospital in London implanted retinal cells on a thin membrane into two patients with the wet form of the same disease. Eye conditions were a natural starting point because the eye is relatively small (requiring fewer cells), somewhat shielded from the immune system, and easy to monitor.
Parkinson’s disease is another major focus. A therapeutic dose for Parkinson’s requires roughly 4.8 million dopaminergic cells, the type of brain cell that the disease destroys. Scaling production to supply even a small Phase 1 trial of 14 patients demands around 70 million precursor cells, and scaling up further for larger trials increases manufacturing requirements by orders of magnitude.
Safety Concerns: Tumor Risk and Genomic Changes
The same quality that makes iPS cells powerful, their ability to become any cell type, also makes them potentially dangerous. Cells that can multiply and transform indefinitely share uncomfortable similarities with cancer cells. When iPS cells were transplanted into immunodeficient mice, some lines formed teratomas, tumors containing a chaotic mix of different tissue types. One particularly unstable cell line produced teratocarcinomas, a malignant form.
The risk appears tied to genomic instability introduced during the reprogramming process. When researchers analyzed the genomes of different iPS cell lines, they found that the most tumor-prone line had acquired five new copy number variations (essentially, chunks of DNA that were duplicated or deleted) during reprogramming. The least tumor-prone lines had gained only one. Mutations in the p53 gene, a critical tumor suppressor, have also been shown to make reprogramming easier while simultaneously increasing the risk of malignancy.
These risks are manageable in principle. Clinical-grade iPS cell lines undergo extensive genomic screening, and the differentiated cells (not the raw iPS cells themselves) are what gets transplanted into patients. But the concern explains why clinical trials are proceeding cautiously and why most remain in early safety-testing phases. Scaling up production adds another layer of uncertainty, since large-scale manufacturing processes can introduce additional genetic changes that wouldn’t appear in small laboratory batches. Ensuring that every batch of cells is genetically stable and free of dangerous mutations is one of the biggest remaining hurdles before iPS cell therapies become routine.